Creatine is the most evidence-backed supplement for slowing the muscle loss that quietly shortens healthspan. Here is what the 2026 evidence says about dosing, form, and which brands actually deliver.
Sarcopenia — the progressive loss of skeletal muscle mass and strength with age — begins in earnest around 40 and accelerates after 60. By 75, the average person has lost 30–40% of peak muscle mass. That loss is not cosmetic. Muscle mass predicts all-cause mortality independently of cardiorespiratory fitness. In the 2018 Alameda County study, grip strength at midlife was a stronger predictor of survival over the following 25 years than smoking, BMI, or blood pressure.
Creatine monohydrate is the only supplement with replicated, randomized evidence that it meaningfully slows this process — and the same mechanism that preserves muscle also protects brain energy metabolism, reduces fall risk, and may support bone density. It is also one of the cheapest, most extensively studied, and safest supplements in existence. Yet it is almost universally neglected in longevity medicine discussions outside the athletic context.
This article covers the longevity case for creatine, what the 2026 evidence actually shows, how to dose it for healthspan rather than hypertrophy, and which brands are worth buying.
Creatine is a nitrogenous organic acid synthesized endogenously from glycine, arginine, and methionine — primarily in the liver and kidneys — and stored predominantly in skeletal muscle (~95%) and the brain (~5%) as phosphocreatine.
The core function: phosphocreatine rapidly regenerates ATP during high-demand cellular events. When a muscle fiber contracts or a neuron fires at high frequency, ATP is depleted faster than mitochondria can replenish it via oxidative phosphorylation. Phosphocreatine donates its phosphate group to ADP, regenerating ATP within milliseconds. This is the reason creatine improves performance in any activity requiring short bursts of high power.